Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
May 2013, Vol 4, No 4
May 2013, Vol 4, No 4
CHOP Disappearing as Standard of Care for Indolent NHL
By
Charles Bankhead
Hematologic Malignancies
,
Leukemia
May 2013, Vol 4, No 4
A long-standing treatment standard for indolent non-Hodgkin lymphoma (NHL) has fallen victim to the chopping block, so to speak, at least in Germany.
Read Article
No Loss of Efficacy with Anthracycline-Free Induction for Acute Lymphoblastic Leukemia
By
Charles Bankhead
Hematologic Malignancies
,
Leukemia
May 2013, Vol 4, No 4
Children with acute lymphoblastic leukemia (ALL) had no drop-off in efficacy with an anthracycline-free regimen that also reduced the long-term risk of cardiotoxicity, reported Andre Baruchel, MD, PhD, Chief of Pediatric Hematology, Robert Debré University Hospital, Paris, France.
Read Article
Liquid Biopsy Improves Detection of Secondary GIST Mutations Causing Drug Resistance
By
Charles Bankhead
Personalized Medicine
May 2013, Vol 4, No 4
Analysis of circulating DNA provides information about secondary mutations that cause drug resistance in patients with previously treated gastrointestinal stromal tumors (GISTs), reported George D. Demetri, MD, Director of the Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, at the 2013 American Association for Cancer Research meeting.
Read Article
Higher HER2 Expression Leads to Better Outcomes with T-DM1 in Patients with Metastatic Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
May 2013, Vol 4, No 4
Washington, DC—Among women with HER2-positive metastatic breast cancer, patients with the highest expression of HER2 had the best outcomes in treatment with ado-trastuzumab emtansine (T-DM1; Kadcyla), according to a biomarker analysis of the phase 3 EMILIA trial which was presented at the 2013 American Association for Cancer Research annual meeting.
Read Article
Gene Expression May Simplify Search for Effective Therapy in Head and Neck Cancer
By
Charles Bankhead
Head and Neck Cancer
,
Personalized Medicine
May 2013, Vol 4, No 4
Therapeutic development in head and neck cancer could eventually hone in on a handful of gene-expression patterns and signaling pathways that can identify a few discrete subtypes of the disease, data from The Cancer Genome Atlas suggest.
Read Article
Tumor Subtype Fails to Explain Racial Disparity in Breast Cancer Survival
By
Charles Bankhead
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
May 2013, Vol 4, No 4
Read Article
Budget Impact Model: Epigenetic Assay Can Help Avoid Unnecessary Repeated Prostate Biopsies, Reduce Spending
Prostate Cancer
,
Solid Tumors
May 2013, Vol 4, No 4
This is an abbreviated version of the original article that was recently published in American Health & Drug Benefits. 2013;6(1):15-24.
Read Article
AUA Revises Its Guidelines for Prostate Cancer PSA Screening
By
Charles Bankhead
Prostate Cancer
,
Solid Tumors
May 2013, Vol 4, No 4
Prostate cancer screening with prostate-specific antigen (PSA) tests should focus on men aged 55 to 69 years, the group that is the most likely to benefit from screening, according to a new clinical guideline issued by the American Urological Association (AUA) at its 2013 annual meeting.
Read Article
Deviation from Clinical Guidelines Takes Toll on Ovarian Cancer Survival
By
Charles Bankhead
Ovarian Cancer
,
Personalized Medicine
,
Solid Tumors
May 2013, Vol 4, No 4
Most women with ovarian cancer receive substandard care that significantly reduces their survival odds, based on a new retrospective review of 13,000 patients that was presented at the 2013 Society of Gynecologic Oncology annual meeting.
Read Article
Novel Immunotherapy Approach Encouraging in Advanced Ovarian Cancer
By
Phoebe Starr
Ovarian Cancer
,
Solid Tumors
May 2013, Vol 4, No 4
Washington, DC—A 2-step immunotherapy approach holds promise for women with advanced recurrent ovarian cancer, a disease that has limited therapeutic options.
Read Article
Page 1 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma